DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for lymph node cancer — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLymph node cancer maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for lymph node cancer is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ATM serine/threonine kinase (ATM) — ATM is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet anpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8OXQ · 2.5 Å · ligand PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER (ANP). Experimental structure, not a prediction.
What the evidence adds up to
In a 2008 review of lymph node count as a quality indicator in cancer care, the authors note that while the number of lymph nodes removed is associated with survival in several cancers, this association rests on observational data and has not been confirmed by randomised surgical trials. They state that improvements in patient outcome by increasing lymph node counts have not yet been demonstrated, and caution that a direct causal connection between node count and survival is unlikely.
A 2009 study of 100 consecutive patients with R0 resected oesophageal adenocarcinoma and pathologically N0 (node-negative) status compared outcomes between 75 patients treated with surgery alone and 25 who received neoadjuvant therapy before surgery. Tumour characteristics were similar between the two groups. Recurrence was significantly more common in the neoadjuvant group: 10 of 25 patients (40%) versus 10 of 75 (13%) in the surgery-only group (p=0.0063). At a median follow-up of 46 months, survival was 49% for patients who were N0 after neoadjuvant therapy versus 85% for patients treated with surgery alone (p=0.005). The authors conclude that neoadjuvant therapy may eradicate lymph node metastases, but that N0 status after such therapy does not produce the same survival as N0 status achieved without it, and that the poor outcomes in the neoadjuvant group suggest these patients initially had node involvement that was downstaged.
Neither abstract reports a drug or treatment that improved outcomes for lymph node cancer. The 2008 paper explicitly states that a survival benefit from increasing lymph node counts has not been demonstrated. The 2009 paper shows that patients who become node-negative after neoadjuvant therapy have worse survival than patients who were node-negative without it. What remains missing is evidence from randomised surgical trials that can establish causality between lymph node count and survival, and any trial design that separates the effect of downstaging from the effect of initial node status on patient outcomes.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Surgical Oncology · 2008 · 49 citations · open access
Is lymph node count an ideal quality indicator for cancer care?
AbstractAlthough lymph node count has substantial appeal as a quality indicator because of the ease of measurement, the presence of variation in the population, the association with survival for many cancers, and the previous success of quality intervention programs, improvements in patient outcome by increasing lymph node counts have not yet been demonstrated. This article discusses potential pitfalls in the use of lymph node count as a quality indicator.
Journal of the American College of Surgeons · 2009 · 19 citations
Survival in Lymph Node Negative Adenocarcinoma of the Esophagus after R0 Resection With and Without Neoadjuvant Therapy: Evidence for Downstaging of N Status
AbstractBACKGROUND: After esophagectomy, many patients who received neoadjuvant therapy have no evidence of lymph node involvement (N0 disease). Whether lymph nodes were initially involved and eradicated by the neoadjuvant therapy (down-staged) or if the nodes were never involved is a subject of debate. To address this issue, we compared clinical outcomes in N0 patients treated with neoadjuvant therapy with outcomes in patients treated with surgery alone. STUDY DESIGN: We reviewed records of 100 consecutive patients who underwent R0 esophagectomy for adenocarcinoma with pathologic N0 status. Seventy-five patients were treated by operation alone and 25 received neoadjuvant therapy. Tumor characteristics including length, depth, lymphovascular invasion, and degree of differentiation were compared and longterm survival was assessed by Kaplan-Meier analysis at a median of 46 months (interquartile range 26 to 77 months). RESULTS: Tumor characteristics were similar between groups. Recurrence was more common in patients who received neoadjuvant therapy compared with those treated with surgery alone (10 of 25 versus 10 of 75, p=0.0063). Patients with N0 disease after neoadjuvant therapy had a significantly worse survival than patients treated by surgery alone (49% versus 85%, p=0.005). CONCLUSIONS: Although neoadjuvant therapy may eradicate lymph node metastases, it does not result in the same outcomes as those achieved in patients with N0 disease treated with surgery alone. The poor clinical outcomes observed in N0 patients after neoadjuvant therapy suggest that they initially had node involvement and were downstaged by eradication of lymph node disease.
AbstractAlthough the number of lymph nodes removed during lymphadenectomy is associated with survival in several cancers, the survival association has been based primarily on observational data, and causality has not been confirmed through randomized surgical trials. Certainly, the number of lymph nodes removed and the extent of lymphadenectomy are likely related to surgical quality at some level; however, a direct connection to survival is less likely.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
